The Laboratory for Thrombosis Research, KU Leuven
Karen Vanhoorelbeke is professor at the University of Leuven, Campus Kulak, Kortrijk, Belgium. She received her PhD in Biochemistry in 1996. During her post-doctoral training, she moved to the field of Thrombosis and Haemostasis in prof. Hans Deckmyns’ lab (University of Leuven). In 2002 she started her own research group where she studies the molecular mechanisms by which the hemostatic proteins van Willebrand factor (VWF) and its cleaving enzyme ADAMTS13 contribute to health and disease. Her research is embedded in several national and international research projects. In 2010 she worked in the lab of prof. dr. Tim Springer at Harvard Medical School, Boston as a visiting professor. She is author and coauthor of more than 96 scientific publications in international peer reviewed journals.
The Laboratory for Thrombosis Research, KU Leuven
Wim obtained the degree of master in Biomedical Sciences at the KULeuven (2004). Subsequently, he joined the research group of Experimental Immunology led by prof. dr. Jan Ceuppens and prof. dr. Stefaan Van Gool at the University Hospital Gasthuisberg in Leuven. In 2009, his work in experimental mouse models focusing on immunotherapeutic approaches for malignant brain tumors resulted in the degree of doctor in Biomedical Sciences (Leuven). From 2010 until now, Wim is postdoc in the Laboratory of Thrombosis Research, project leader at PharmAbs (www.pharmabs.org) - the KULeuven Antibody Center, lecturer @ Kulak and manager of the H2020 “Profile” Marie Curie project.
The Laboratory for Thrombosis Research, KU Leuven
Nick Geukens obtained a Master of Science degree in Biochemistry of the KU Leuven, Belgium. He obtained his PhD in Sciences at the KU Leuven, Belgium in 2002. Since 2008 he is coordinator of PharmAbs, the KU Leuven Antibody Center (www.pharmabs.org), an interdisciplinary innovation and valorisation platform at KU Leuven with the specific mission to develop novel antibody-based diagnostics and therapeutics. He is training manager of the PROFILE project.
Prof. dr. Jan Voorberg heads the laboratory of Cellular Hemostasis of Sanquin Research. Within his group cell biological, immunological and biochemical approaches are integrated to advance our understanding of the interplay between vascular and immune cells with the hemostatic system. During the last five years emphasis has been on mechanistic studies to define the cellular networks that contribute to the biogenesis and release of Weibel-Palade bodies from endothelial cells. Another line of research focuses on the auto-immune disorder thrombotic thrombocytopenic purpura (TTP) which targets the von Willebrand factor cleaving protease ADAMTS13. Jan Voorberg has published over 100 papers in peer-reviewed journals; he is/has been (co-)promoter of more than 20 PhD students.
Kaia Palm, PhD, is CEO and founder of Protobios since 2003. She received her MSc in Chemistry/Physics from Tartu State University in 1987 (Cum Laude with Honors) and her PhD in molecular neurobiology from the Faculty of Medicine, Karolinska Institute in 1998. She has more than 10 years of experience in diagnostics and drug discovery in industry and academia and has published over 15 scientific articles and book chapter reviews.
Toomas Neuman (PhD) is an expert in molecular and cell biology and the founder of several biotechnology companies in US and Estonia. His team performed the first autologous stem cell therapy on a Parkinson's disease patient at the Cedars Sinai Medical Center (Los Angeles, CA) in 1998. He was a founder of Neurogeneration, later Celmed Biosciences (Los Angeles, CA). Company raised $40 mln for development of cell therapy procedures. In 2000 Toomas and his colleagues founded CeMines, Inc. to develop molecular diagnostic techniques for early detection and monitoring of cancer using proprietary fingerprinting platform technology. Toomas Neuman is a Professor at the Tallinn University of Technology (Estonia). He also founded several biotechnology companies including Protobios, FibroTx, Cellin Technologies and BiotaP in Estonia. Toomas Neuman is the author of more than 70 scientific publications in international journals and has presented his work at numerous scientific meetings. He is an inventor with 8 patents and 7 patent applications.
Andres Männik is Chief Technology Officer at Icosagen, Estonia. He received his PhD (Molecular Virology) in 2003. During post-doctoral years he worked in biotechnology companies FIT Biotech and Icosagen. As senior scientist or principal investigator he has been involved in several developments and international research projects focused on gene vaccination, gene therapy, cell-based assays, monoclonal antibody development and recombinant protein production.
Chris Reutelingsperger is Professor of Biochemistry of Apoptosis at the Cardiovascular Research Institute (CARIM) of Maastricht University. He is Principal Investigator of the research theme “Vascular Aspects” of Main Theme 1 of the CARIM research program and CSO of the biotech company PharmaTarget. His interests research focus on cell death programs, phagocytosis, autophagy, annexins, with emphasis on annexins A1 and A5, and vitamin K-dependent proteins. His strategy encompasses establishing collaborations with clinical research and industry.
Gerry Nicolaes studied chemistry from 1987 till 1993 in Utrecht, the Netherlands, where he specialised in Biochemistry. In 1997 he received his PhD from the Faculty of Medicine of the Maastricht University, which was awarded a ``cum laude`` distinction. After a short prolongation of the thesis work on the prothrombotic effects of oral contraceptives till early 1998, which received worldwide attention, he accepted a postdoctoral position at the Wallenberg Laboratory, University of Lund, Sweden with Prof. Björn Dahlbäck. From late 2000 till present, he continued research on structure-function studies of proteins and on in silico drug discovery & design studies at the Biochemistry Department of CARIM. Gerry published over 70 peer-reviewed scientific articles and supervised 8 doctorate candidates.
Robin holds an MA in International Relations from Utrecht University. He joined the European Hematology Association (EHA) in the summer of 2016 as European Affairs coordinator. As the leading representative of hematology and hematologists in Europe, EHA advocates for more and better research funding opportunities, improved regulation and enhanced availability and affordability of medicines, as well as for harmonized standards and excellence in education and training. Previously, Robin worked as a program manager for a non-profit organization for nearly twenty years, designing and arranging international study programs – often focused on (European) public affairs – for leaders and policymakers from government, business, academia and politics.
EHA wholeheartedly endorses and supports the PROFILE project.
Liselotte Brix is COO at and co-founder of Immudex, a company specialized in monitoring antigen-specific T-cell responses. She holds a Ph.D in immunology and biotechnology and has 15+ years scientific experience with TCR-MHC interactions in relation to cancer, infectious and autoimmune disease. She joined the Danish diagnostic company Dako, Copenhagen in 2005 and was before that assistant professor at the Danish Pharmaceutical University, Copenhagen and at Aarhus University.
Agnès Veyradier is a hematologist (MD; PhD) specialized in hemostasis disorders. She was trained in Paris-Sud University School of Medicine and Research Laboratories (France). She has been a professor of Hematology since 2005 in Paris-Sud University and since 2014, in Paris-Diderot University. She is the head of the Hematology Department in Hospital Lariboisière, Paris. Since 2006, she has been the national coordinator of the French National Reference Center for von Willebrand disease and the responsible biologist for the ADAMTS13 laboratory from the French Reference Center for Thrombotic Microangiopathies, both qualified by the National Plan for Rare diseases of the French Health Ministry. She is the head of a research team dedicated to “Thrombotic Microangiopathies” (EA3518 Clinical Research in Hematology, immunology and transplantation) located at the University Institute of Hematology of Hospital Saint Louis, Paris.
Paul Coppo is Professor of Hematology at Pierre et Marie Curie University and Doctor at Saint-Antoine Hospital. He received his PhD in 2006 in William Vainchenker’s lab (Institut Gustave Roussy). His research and medical activity focuses on hemato-immunologic diseases. He is the Head of the French Reference Center for Thrombotic Microangiopathies (CNR-MAT), which research projects involve pathophysiology and immunomodulation in autoimmune TTP. He is author and coauthor of more than 100 scientific publications in international peer reviewed journals.
Marta Palicio is Chief Innovation Officer at Biokit. Her role is to explore new opportunities and technologies related with in vitro diagnosis. Biokit is currently developing several IVD test for diagnosis of hemostasis-related conditions. Marta has more than fifteen years of experience in biomedical research and biotechnology. Between 2000 and 2003, she worked in Genset, a French pharmacogenomics company, where she coordinated programs looking for therapeutic targets for schizophrenia and bipolar disorders. Afterwards, she worked as International Affairs Manager at Eurasanté, an agency specialised in the economic development of the health sector for the Lille Nord-Pas de Calais Region (France). Between 2006 and 2012, she worked at Oryzon, a Spanish biomarker and target discovery company as Project developer and later as Scientific Business Developer.
Early Stage Researchers
After graduating master degree (2012) in biology at the University of Tartu (Estonia), Kadri worked in biotechnology company Icosagen Cell Factory for 3.5 years, developing novel technologies and providing research services to the biopharmaceutical and biotechnology industries and to academia. In 2016 she started her PhD studies in the Laboratory of Thrombosis Research to unravel the role of specific autoantibodies in the pathophysiology of acquired TTP in the PROFILE network.
Johana graduated as a Master in Clinical and Toxicological Analysis at the Faculty of Science of the Charles University in Prague. There she participated in a research project focused on cytochromes P450 and development of anti-peptide antibodies directed against them.
In 2016 she started her PhD studies at Sanquin and her research is focused on profiling of CD4+ T cell responses in patients with acquired TTP.
After undertaking an exchange program at KU Leuven, Silvia completed a Master in Pharmaceutical Biotechnology (2014) at the University of Perugia (Italy), a well-defined master program that oriented her towards the fields of molecular pharmacology and molecular biology respectively. Starting from March 2016, she joined the Laboratory for Thrombosis Research, where she started a PhD within the PROFILE network. During her PhD, she will further investigate the immune response of acquired TTP patients, taking advantage of high throughput technologies in order to determine the complete immune profile of anti-ADAMTS13 autoantibodies, therefore linking new biomarkers with patients prognosis.
Leydi Carolina Velasquez Pereira
Carolina graduated as Master in Biomedical Basic Sciences at the Industrial University of Santander (Colombia); it involved the study of polymorphism in the lipoprotein lipase gene as genetic markers for stroke. Prior to her graduate work, she obtained a Bachelor degree in Bacteriology and Clinical laboratory at the Industrial University of Santander. In 2016, she started her PhD in the laboratory for Thrombosis research, within the PROFILE training network. Her research focus is to establish an immune profile of autoantibodies as a new type of biomarker for stratification of acquired thrombotic thrombocytopenic purpura patients and link them with the disease prognosis.
Nuno graduated as a Master in Pharmaceutical Sciences at the Faculty of Pharmacy of the University of Lisbon (Portugal). There he participated in research projects regarding the safety and efficacy of Portuguese Traditional Herbal Preparations in diabetes. Afterwards he moved to Porto (Portugal) where he participated in projects about development of new treatments for parasitic infections (African Sleeping Sickness and Leishmaniasis). In 2016 he started his PhD at Icosagen and his research focus is on the development of new treatment strategies for acquired TTP.
Boğaç graduated as a Master in “ in silico Drug Design” at the Faculty of Life Sciences of the Paris Didérot University (France). There he learned and discovered the insights of the drug design and completed a 6-month internship at University of Copenhagen where he mostly studied about the prediction of site of metabolism of non-steroid anti-inflammatory drugs (NSAIDs). In 2016 he started his PhD at PharmaTarget (Maastricht) and his research focus is structural bioinformatics and rational drug discovery and design to support and provide novel Acquired TTP Therapies.
All the patients participating and helping us taking further steps in this journey!
Funded by the Horizon 2020
Framework Programme of the